OBJECTIVE: 6-Mercaptopurine (6-MP) and azathioprine (AZA) are effective in the treatment of IBD; however, drug-induced hepatotoxicity has been reported in 10-15% of pediatric patients and has been associated with the 6-MP metabolite 6-methylmercaptopurine ribonucleotide (6-MMPR) at levels >5,700 pmol/8 x 10(8) RBC. The aim of this study was to assess the prevalence of 6-MP/AZA hepatotoxicity and its correlation with serum 6-MMPR levels in adult IBD patients. METHODS: Aminotransferases, bilirubin, and 6-MP metabolite levels were measured in 173 adult IBD patients treated with 6-MP or AZA from November 2002 to December 2003. Hepatotoxicity was defined as AST and/or ALT >2x upper limit of normal or cholestasis. RESULTS: Eight patients (4.6%) met criteria for a diagnosis of 6-MP/AZA-induced hepatotoxicity. The mean 6-MMPR level in these 8 patients was 10,537 pmol/8 x 10(8) RBC versus 3,452 pmol/8 x 10(8) RBC in the nonhepatotoxic group (P < 0.001). Risk of hepatotoxicity above the third quartile (6-MMPR > 5,300) was 5 times that below the third quartile (11.4%vs 2.3%, P < 0.05); however, nearly 90% of all patients with 6-MMPR > 5,300 pmol/8 x 10(8) RBC had no hepatotoxicity, while almost 40% of subjects with hepatotoxicity had 6-MMPR levels below this cutoff. CONCLUSIONS: 6-MP/AZA-induced hepatotoxicity is uncommon in the adult population. Although hepatotoxicity is associated with higher mean 6-MMPR levels, the sensitivity and specificity of 6-MMPR for drug-induced hepatotoxicity was poor. Monitoring liver tests in patients on 6-MP/AZA is suggested, and dose reduction or cessation of 6-MP/AZA, even with high 6-MMPR levels, should be reserved for patients with elevated aminotransferases.
OBJECTIVE:6-Mercaptopurine (6-MP) and azathioprine (AZA) are effective in the treatment of IBD; however, drug-induced hepatotoxicity has been reported in 10-15% of pediatric patients and has been associated with the 6-MP metabolite 6-methylmercaptopurine ribonucleotide (6-MMPR) at levels >5,700 pmol/8 x 10(8) RBC. The aim of this study was to assess the prevalence of 6-MP/AZAhepatotoxicity and its correlation with serum 6-MMPR levels in adult IBDpatients. METHODS: Aminotransferases, bilirubin, and 6-MP metabolite levels were measured in 173 adult IBDpatients treated with 6-MP or AZA from November 2002 to December 2003. Hepatotoxicity was defined as AST and/or ALT >2x upper limit of normal or cholestasis. RESULTS: Eight patients (4.6%) met criteria for a diagnosis of 6-MP/AZA-induced hepatotoxicity. The mean 6-MMPR level in these 8 patients was 10,537 pmol/8 x 10(8) RBC versus 3,452 pmol/8 x 10(8) RBC in the nonhepatotoxic group (P < 0.001). Risk of hepatotoxicity above the third quartile (6-MMPR > 5,300) was 5 times that below the third quartile (11.4%vs 2.3%, P < 0.05); however, nearly 90% of all patients with 6-MMPR > 5,300 pmol/8 x 10(8) RBC had no hepatotoxicity, while almost 40% of subjects with hepatotoxicity had 6-MMPR levels below this cutoff. CONCLUSIONS:6-MP/AZA-induced hepatotoxicity is uncommon in the adult population. Although hepatotoxicity is associated with higher mean 6-MMPR levels, the sensitivity and specificity of 6-MMPR for drug-induced hepatotoxicity was poor. Monitoring liver tests in patients on 6-MP/AZA is suggested, and dose reduction or cessation of 6-MP/AZA, even with high 6-MMPR levels, should be reserved for patients with elevated aminotransferases.
Authors: Einar S Björnsson; Jiezhun Gu; David E Kleiner; Naga Chalasani; Paul H Hayashi; Jay H Hoofnagle Journal: J Clin Gastroenterol Date: 2017-01 Impact factor: 3.062
Authors: David Gurwitz; Cristina Rodríguez-Antona; Katherine Payne; William Newman; Javier P Gisbert; Emma Gutiérrez de Mesa; Dolores Ibarreta Journal: Eur J Hum Genet Date: 2009-02-18 Impact factor: 4.246
Authors: Andres J Yarur; Maria T Abreu; Amar R Deshpande; David H Kerman; Daniel A Sussman Journal: World J Gastroenterol Date: 2014-04-07 Impact factor: 5.742
Authors: Elsa L S A van Liere; Ahmed B Bayoumy; Chris J J Mulder; Ben Warner; Bu Hayee; Bilal A Mateen; Jonathan D Nolan; Nanne K H de Boer; Simon H C Anderson; Azhar R Ansari Journal: Dig Dis Sci Date: 2021-11-02 Impact factor: 3.487
Authors: Mark M T J Broekman; Hennie M J Roelofs; Dennis R Wong; Mariska Kerstholt; Alex Leijten; Frank Hoentjen; Wilbert H M Peters; Geert J A Wanten; Dirk J de Jong Journal: Cell Biol Toxicol Date: 2015-04-28 Impact factor: 6.691